Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates

分组1 - Editas Medicine reported a quarterly loss of $0.63 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.41, representing an earnings surprise of -53.66% [1] - The company posted revenues of $3.58 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 320.94%, compared to revenues of $0.51 million in the same quarter last year [2] - Editas shares have increased approximately 73.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.4% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.39 on revenues of $0.85 million, and for the current fiscal year, it is -$1.93 on revenues of $11.24 million [7] - The Medical - Biomedical and Genetics industry, to which Editas belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8]